The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: A meta-analysis

Gene

Volumn 531, Issue 2, 2013, Pages 476-488

  Liu, Yuan Yuan ^a   Li, Changping ^a   Cui, Zhuang ^a   Fu, Xiaomeng ^a   Zhang, Shu ^a   Fan, Lin Lin ^a   Ma, Jun ^a   Li, Guang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

ABCB1 C3435T; Association; Meta analysis; Polymorphism; Tacrolimus pharmacokinetics

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; CYSTEINE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THREONINE; THYMOCYTE ANTIBODY;

ARTICLE; CAUCASIAN; COCHRANE LIBRARY; COMPUTER PROGRAM; DISEASE ASSOCIATION; ETHNIC GROUP; GENOTYPE; HOMOZYGOTE; HUMAN; LIVER TRANSPLANTATION; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ABCB1 C3435T; ASSOCIATION; CI; CONFIDENCE INTERVALS; META-ANALYSIS; P-GLYCOPROTEIN; P-GP; POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISMS; SNPS; TACROLIMUS PHARMACOKINETICS; WEIGHTED MEAN DIFFERENCES; WMD;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TACROLIMUS; TRANSPLANTATION CONDITIONING;

EID: 84885430894     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.09.024     Document Type: Article

References (59)

1. Anglicheau D., et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 2003, 14:1889-1896.
2. Barrera-Pulido L., et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant. Proc. 2008, 40:2949-2951.
3. Bonhomme-Faivre L., et al. Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. Am. J. Health Syst. Pharm. 2009, 66:1645-1651.
4. Cholongitas E., et al. Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin. Clin. Transplant. 2011, 25:614-624.
5. Chowbay B., Li H., David M., Bun Cheung Y., Lee E.J.D. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br. J. Clin. Pharmacol. 2005, 60:159-171.
6. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
7. Dai D., et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001, 11:597-607.
8. Dai Y., et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos. 2006, 34:836-847.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
10. Elens L., et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet. Genomics 2007, 17:873-883.
11. Fu S.J., Wang Y.B., Yu L.X., Li Q., Xiao L.L. Factors responsible for inter-individual variations in dosage/concentration of tacrolimus in renal transplant recipients. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28:2161-2164.
12. Fukudo M., et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther. 2006, 80:331-345.
13. Fukudo M., et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet. Genomics 2008, 18:413-423.
14. Fung K.L., Gottesman M.M. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta Proteins Proteomics 2009, 1794:860-871.
15. Geissler E.K., Schlitt H.J. Immunosuppression for liver transplantation. Gut 2009, 58:452-463.
16. Gijsen V.M., Madadi P., Dube M.P., Hesselink D.A., Koren G., de Wildt S.N. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann. Transplant. 2012, 17:111-121.
17. Goto M., et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002, 12:451-457.
18. Goto M., et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004, 14:471-478.
19. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 2004, 351:2715-2729.
20. Hawwa A.F., McElnay J.C. Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Expert Opin. Drug Saf. 2011, 10:9-22.
21. Hawwa A.F., McKiernan P.J., Shields M., Millership J.S., Collier P.S., McElnay J.C. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br. J. Clin. Pharmacol. 2009, 68:413-421.
22. Hoffmeyer S., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. 2000, 97:3473-3478.
23. Hosohata K., et al. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm. Res. 2009, 26:1590-1595.
24. Jiang Z.-P., Wang Y.-R., Xu P., Liu R.-R., Zhao X.-L., Chen F.-P. Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin. Pharmacol. Toxicol. 2008, 103:433-444.
25. Jin J., Wu L.H., Wang W.L., Yu S.F., Yan S., Zheng S.S. Impact of multidrug resistance 1 gene polymorphism on tacrolimus dose and concentration-to-dose ratio in Chinese liver transplantation recipients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005, 22:616-620.
26. Jin Z., Zhang W.x., Chen B., Mao A.W., Cai W.M. Stepwise regression analysis of the determinants of blood tacrolimus concentrations in Chinese patients with liver transplant. Med. Chem. 2009, 5:301-304.
27. Jun K.R., et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 2009, 87:1225-1231.
28. Li D., Lu W., Zhu J.Y., Gao J., Lou Y.Q., Zhang G.L. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J. Clin. Pharm. Ther. 2007, 32:505-515.
29. Li D., Zhu J.-Y., Gao J., Wang X., Lou Y.-Q., Zhang G.-L. Polymorphisms of tumor necrosis factor-α, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin. Chim. Acta 2007, 383:133-139.
30. Li Y., et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transpl. Immunol. 2012, 27:12-18.
31. Li Y., et al. The associations of IL-18 serum levels and promoter polymorphism with tacrolimus pharmacokinetics and hepatic allograft dysfunction in Chinese liver transplantation recipients. Gene 2012, 491:251-255.
32. Marquet P., Djebli N., Picard N. Pharmacogenetics and immunosuppressor drugs: impact and clinical interest in transplantation. Ann. Pharm. Fr. 2007, 65:382-389.
33. Masuda S., Inui K.-i. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol. Ther. 2006, 112:184-198.
34. Mourad M., et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 2008, 85:S19-S24.
35. Provenzani A., et al. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann. Transplant. 2009, 14:23-31.
36. Provenzani A., et al. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int. J. Mol. Med. 2011, 28:1093-1102.
37. Provenzani A., et al. Unusual high dose of tacrolimus in liver transplant patient, a case report. Int. J. Clin. Pharmacol. 2012, 34:269-271.
38. Rahsaz M., et al. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population. Exp. Clin. Transplant. 2012, 10:24-29.
39. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 1993, 268:6077-6080.
40. Sai K., et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003, 13:741-757.
41. Sakaeda T., Nakamura T., Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003, 4:397-410.
42. Schwartz M., Holst B., Facklam D., Buell D. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US multicenter FK 506 dose optimization. Transplant. Proc. 1995, 27:1107.
43. Shi Y., et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene 2013, 512:226-231.
44. Staatz C.E., Goodman L.K., Tett S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin. Pharmacokinet. 2010, 49:141-175.
45. Staatz C.E., Goodman L.K., Tett S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin. Pharmacokinet. 2010, 49:207-221.
46. Tang H.-L., Xie H.-G., Yao Y., Hu Y.-F. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet. Genomics 2011, 21:713-720.
47. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7735-7738.
48. Uesugi M., Masuda S., Katsura T., Oike F., Takada Y., Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics 2006, 16:119-127.
49. Utecht K.N., Hiles J.J., Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am. J. Health Syst. Pharm. 2006, 63:2340-2348.
50. Venkataramanan R., et al. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 1995, 29:404-430.
51. Venkataramanan R., et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J. Clin. Pharmacol. 2001, 41:542-551.
52. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics 2005, 15:693-704.
53. Wei-lin W., et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl. 2006, 12:775-780.
54. Wildt S., et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur. J. Clin. Pharmacol. 2011, 67:1231-1241.
55. Wu C.Z., et al. A fast SSP-PCR method for genotyping the ATP-binding cassette subfamily B member 1 gene C3435T and G2677T polymorphisms in Chinese transplant recipients. Tumori 2009, 95:338-342.
56. Yamauchi A., et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002, 74:571-572.
57. Yu X., et al. Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS One 2011, 6:e25933.
58. Zahir H., McCaughan G., Gleeson M., Nand R.A., McLachlan A.J. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br. J. Clin. Pharmacol. 2004, 57:298-309.
59. Zhang X., Wang Z., Fan J., Liu G., Peng Z. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur. J. Clin. Pharmacol. 2011, 67:803-813.